Osteologie, Inhaltsverzeichnis Osteologie 2023; 32(04): 230-233DOI: 10.1055/a-2199-2028 Editor’s Introduction, the enhanced Editorial Das Labor der OsteologInnen The Osteologist’s Laboratory Franz Jakob 1 Bernhard-Heine-Centrum für Bewegungsforschung, Julius-Maximilians-Universität Würzburg, Würzburg, Germany , Barbara Obermayer-Pietsch 2 Universitätsklinik für Innere Medizin und Universitätsklinik für Frauenheilkunde & Geburtshilfe, Medizinische Universität Graz, Graz, Austria , Walter Fassbender 3 Labormedizin, Leitung Medizin, Medica Medizinische Laboratorien Dr F Kaeppeli AG, Zurich, Switzerland › Institutsangaben Artikel empfehlen Abstract Artikel einzeln kaufen Volltext Referenzen Literatur 1 Schini M, Vilaca T, Gossiel F. et al. Bone Turnover Markers: Basic Biology to Clinical Applications. Endocr Rev 2023; 44: 417-473 2 Foessl I, Dimai HP, Obermayer-Pietsch B. Long-term and sequential treatment for osteoporosis. Nat Rev Endocrinol 2023; 19: 520-533 3 Cavalier E, Lukas P, Bottani M. et al. European Biological Variation Study (EuBIVAS): within- and between-subject biological variation estimates of beta-isomerized C-terminal telopeptide of type I collagen (beta-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin, intact fibroblast growth factor 23 and uncarboxylated-unphosphorylated matrix-Gla protein-a cooperation between the EFLM Working Group on Biological Variation and the International Osteoporosis Foundation-International Federation of Clinical Chemistry Committee on Bone Metabolism. Osteoporos Int 2020; 31: 1461-1470 4 Diemar SS, Dahl SS, West AS. et al. A Systematic Review of the Circadian Rhythm of Bone Markers in Blood. Calcif Tissue Int 2023; 112: 126-147 5 Eastell R, Pigott T, Gossiel F. et al. DIAGNOSIS OF ENDOCRINE DISEASE: Bone turnover markers: are they clinically useful. Eur J Endocrinol 2018; 178: R19-R31 6 Liedtke D, Hofmann C, Jakob F. et al. Tissue-Nonspecific Alkaline Phosphatase-A Gatekeeper of Physiological Conditions in Health and a Modulator of Biological Environments in Disease. Biomolecules 2020; 10 7 Dincel AS, Jorgensen NR. Metabolism I-IJCoB New Emerging Biomarkers for Bone Disease: Sclerostin and Dickkopf-1 (DKK1). Calcif Tissue Int 2023; 112: 243-257 8 Gossiel F, Ugur A, Peel NFA. et al. The clinical utility of TRACP-5b to monitor anti-resorptive treatments of osteoporosis. Osteoporos Int 2022; 33: 1357-1363 9 Grillari J, Makitie RE, Kocijan R. et al. Circulating miRNAs in bone health and disease. Bone 2021; 145: 115787 10 Vieira JG. PTH Assays: Understanding What We Have and Forecasting What We Will Have. J Osteoporos 2012; 2012: 523246 11 Jakob F, Thomasius F. et al. Sequenztherapie der Osteoporose – Theorie und moderne Praxiskonzepte: Osteogene Signalwege. Bremen, London, Boston: UNI-MED Verlag Bremen; 2023
